These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19828009)

  • 1. Novel agents for the treatment of adenocarcinoma of the pancreas.
    Mackenzie RP; McCollum AD
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1473-85. PubMed ID: 19828009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
    Abbruzzese JL
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):2-8. PubMed ID: 12577227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
    Rivera F; López-Tarruella S; Vega-Villegas ME; Salcedo M
    Cancer Treat Rev; 2009 Jun; 35(4):335-9. PubMed ID: 19131170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
    Saif MW
    JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel advances in pancreatic cancer treatment.
    Vulfovich M; Rocha-Lima C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):993-1002. PubMed ID: 18533808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Reni M; Cereda S; Galli L
    Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
    Kourie HR; Gharios J; Kattan J
    Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of metastatic pancreatic cancer.
    Ko AH; Tempero MA
    J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal depletion goes on trial in pancreatic cancer.
    Garber K
    J Natl Cancer Inst; 2010 Apr; 102(7):448-50. PubMed ID: 20339135
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
    J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
    Ryu JK
    Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
    Saif MW
    JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gemcitabine and pancreatic cancer].
    Prost P; Ychou M; Azria D
    Bull Cancer; 2002 Aug; 89 Spec No():S91-5. PubMed ID: 12449037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.
    Kudgus RA; Szabolcs A; Khan JA; Walden CA; Reid JM; Robertson JD; Bhattacharya R; Mukherjee P
    PLoS One; 2013; 8(3):e57522. PubMed ID: 23483913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
    Nebot-Villacampa MJ; Zafra-Morales R; Alfaro-Olea A; Marín-Gorricho R; Casajús-Navasal A; Uriarte-Pinto M
    J Oncol Pharm Pract; 2020 Apr; 26(3):603-611. PubMed ID: 31315550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
    Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
    JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.